Dia-chem srl of Naples at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Dia-chem srl

Viale Privato Rai, 7, 80131 Naples
Telephone +39 081 5870231
Fax +39 081 5873419

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Hall map

MEDICA 2021 hall map (Hall 1): stand F20

Fairground map

MEDICA 2021 fairground map: Hall 1

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Our products

Product category: Polymerase chain reaction (PCR)


Oncohaematological pathologies can use efficient tools for the diagnosis and monitoring with the advent of techniques for biomolecular diagnosis, based on technique of Polymerase Chain Reaction (PCR), for the analysis of monoclonality, rearrangements, crhomosomic translocations and for early and differential diagnosis, in addition to the evaluation of minimal residual disease (MRD). Dia-Chem LTD offers high specificity, sensitivity full panel systems, easy to perform for the diagnosis of oncohaematological diseases.
-The Kit Ampli Set Lymphoma B (VDJ) is used to identify, with PCR, the rearrangement of heavy chain (IgH). The primers used are: Fr1A, Fr2A and Fr3A, homologous to the conserved sequences of the regions "framework II-III", and the region "joining" (JH) of LJH and VLJH.
-The Kit Ampli set Lymphoma T-cell receptor Y allows you to identify, through the use of PCR, the gene rearrangements of the T cell receptor (TCR) in normal and neoplastic lymphocytes. The primers used are: TCR V2-V3-V4-V8 V5--V9- V10-V11-V12, homologous to each segment TCR V and JGT1-2-3-4 homologous segments "joining (J)."
- The kit Ampli set Lynphoma TCR receptor allows the identification using three PCR mix rearrangements: A (V-J), B (V-J) C (D-J). Molecular analysis of TCR genes is an important indicator of the clonality in suspected proliferation cells of T lymphoma.
- The kit Ampli set Lymphoma cells allows the analysis of the chromosomal translocation t(14;18) present in 85% of patients with follicular lymphoma and in 30% of patients with non-Hodgkin limfoma spread (NHL). In this translocation the BCL2 proto-oncogene on chromosome 18 is translocated in the region of the genes of the immunoglobulin heavy chain (IgH) on chromosome 14, creating a hybrid gene product BCL2/IgH. The region of major break-point (MBR) is located in the 3'untranslated (3'UTR), and the minor break-point region (mcr) is located 20 kb downstream.
- The Kit Ampli set Mant. Lymph. t(11;14)(Q13;Q32) enables you to diagnose mantle cell lymphoma (MCL), which represents 6% of non-Hodgkin's lymphomas. Genetic alterations associated with the disease are constituted by translocation t(11;14)(q13;q32) in which the rearrangement of genomic DNA involves the BCL1 region on chromosome 11 encoding for the cyclin D1 and the gene for immunoglobulins IgH on cromosoma1.
- The kit Ampli set BCR/ABL p190 and p210 t(9-22) allows the analysis of the Philadelphia chromosome (Ph), described in the cells of chronic myelogenous leukemia (CML), is also found in about 2-10 % of acute lymphoblastic leukemia (ALL) in childhood and in 20-50% of adults, with an incidence that increases progressively with age. The Philadelphia chromosome is an aberrant chromosome 22 formed as a result of a translocation 9:22. Translocation Ph always produces the conjunction of the sequence 3 In the CML fusion transcripts coding for a protein of 210 kD BCR-ABL, called p210BCR / ABL. About 40% of ALL with Ph + show the same rearrangement seen in CML; the remaining 60% of Ph + ALL with show a protein of 190 kD, called p190BCR / ABL. The Analysis by Reverse Transcription-PCR (RT-PCR) of the fusion genes is based on the design of primers to opposite sides of the regions of fusion.
- The kit Ampli set PML-RARa identifies the translocation t(15;17) associated with acute promyelocytic leukemia (APL). The two genes are involved in the translocation PML, coding for a putative new transcription factor, on chromosome 15, and the gene of the retinoic acid receptor (RARa) on chromosome 17. The breakpoints on chromosome 17 are located in a DNA fragment of 15 kb in intron 2 of the RARa gene. In contrast, three regions of the PML locus are involved in translocations: intron 6 (bcr1; 55% of cases), exon 6 (bcr2; 5% of cases) and intron 3 (bcr3; 40% of cases). Chimeric PML-RARa and PML- RARa are formed as a result of reciprocal translocation between the PML and RARa loci.
- The Kit Ampli set FTL3 ITD allows ITD mutation detection (ITD Internal Tandem Duplication) within the domain of the gene FTL3, member tyrosyne receptor kinase class III. It consists of a gene duplication whose range is between 21 and 174 bp. Diagnosis by PCR of ITD allows you to practice the patient treatment with specific inhibitors of receptor tyrosine kinase.
- The Kit Ampli Set FTL3 D835-Mt allows the identification of the mutation D835-Mt, which consists of a nucleotide substitution such that the amino acid encoded is no longer aspartic acid (D), but more frequently a tyrosine residue or D835Y a residue of valine D835V. Rarely the mutation is D835H, D835E or D835N. The mutation involves the loss of a restriction site for the enzyme Eco RV. The mutation is detected by PCR with specific oligonucleotides and subsequent enzymatic digestion.
- The kit Ampli set JAK2 V617F allows to identify, through the use of allele-specific PCR (ARMS-PCR Amplification Refractory Mutation System-PCR), the wild-type allele (normal) and mutated. In particular, we obtain an amplified 229 bp for the normal allele and one of 279 bp for the mutant. The V617F mutation, is due to a nucleotide substitution G> T at nucleotide 1849 of exon 14, which causes the substitution of valine with phenylalanine at codon 617 (GTC> TTC). This mutation involves a portion of the domain of JAK2 pseudokinasic JH2, crucial in controlling the activity of inhibitory JH1. It is an acquired somatic mutation, present only in myeloid cells (erythroid, granulocyte-macrophage line, platelet lineage) heterozygous or homozygous state. The mutation is defined as "gain-of-function mutation" as it results in a constitutive activation of the JAK- STAT, which is able to confer proliferative advantage and cytokine-independent growth of hematopoietic cells.
-The Kit Ampli set AML1ETO t(8:21) allows identification of the translocation t(8:21) associated with acute myeloid leukemia (AML), which account for 10% of pediatric acute leukemias. Are often associated with more aberrations of the karyotype, such as the loss of the Y sex chromosome in males and of X inactivation in females. Following the translocation t(8:22) creating a fusion protein consisting of AML1 and ETO co-repressor that represses transcription and immortalizes hematopoietic progenitor cells.

More Less

Product category: Polymerase chain reaction (PCR)


Haemochromatosis is a common recessive disorder characterised by progressive iron overload. Unfortunately it is little considered and it is often accidentally discovered in periodic check or due to the development of its complications. In Italy and in some European regions there are 2-5 affected individuals in 1000 people and 9-15 carriers in 100. Haemochromatosis is regarded as the most common genetic disorder in the west hemisphere. In 1996 the HFE gene has been detected and two mutations, C282Y and H63D, have been described. Most affected patients with haemochromatosis are homozygous for the C282Y mutation (80-100%), whereas a few are compound heterozygous for the C282Y and H63D. Homozygote for the H63D mutation is not clearly linked to haemochromatosis. The kit allows the simultaneous detection of C282D and H63D mutations using the Polymerase. Chain reaction PCR and restriction analysis using the PmI restriction enzyme

More Less

Product category: Polymerase chain reaction (PCR)

five kits for: detection of Y chromosomal microdeletions and gr/gr deletions, FSHR E FSH polimorphysms.

DIA-CHEM srl introduces five kits for: detection of Y chromosomal microdeletions and gr/gr deletions, FSHR E FSH polimorphysms. Y-chromosomal microdeletions are the second most frequent genetic cause of male infertility. Microdeletions occur in about one in 4000 men in general population but its frequency is significantly increased among infertile men. Azoospermic men have a higher incidence of microdeletions than oligospermic men (frequency 2-10%).
Due to the results of an external quality control, the need of guide-lines for the detection of Y chromosomal microdeletions arised.Therefore, the European Academy of Andrology (EAA) and the European Molecular Genetics Quality Network (EMQN) supported the publication of two "laboratory guidelines for molecular diagnosis of Y-chromosomal microdeletions" (Simoni et al, 1999-2004) and started offering external quality assessment (EQA) in accordance with the EAA/EMQN guidelines.
The kit Ampli set Y Chromosome UE and FAM Y Chromosome UE allows the detection of Y chromosome microdeletions inside the three regions AZFa, AZFb, AZFc using 2 multiplex PCR mix. The STS (Sequenced Tagged Sites) investigated are assessed by the guide lines of EAA, as the internal controls ZFX/ZFY and SRY. The detection is performed on agarose gel or by fragment analysis (cat.1.501FAM). The kit Ampli set Y Chromosome Extension allows to confirm microdeletions identified by the first step kit and to analyze the entire deleted region, assessing if a deletion is partial or complete.The choice of markers is based on the EAA Guide-lines. Ampli set gr/gr Ychromosome: The AZFc region is particuraly susceptible to homologous intrachromosomal recombination events, due to its repetitive structure, which may leads to deletions. New types of AZFc deletions called partial deletions or gr/gr deletions, have been reported.They remove about half of AZFc content, including two DAZ genes (CDY1 and BPY2). Italian gr/gr carriers have a 7.9 -fold increased risk of impaired spermatogenesis compared with men without such a deletion. The Dia-chem srl gr/gr Y chromosome allows to detect the presence of gr/gr partial deletions using specific primers for Sy1291 and SY1191 and for ß-globin as internal
control of multiplex PCR. Ampli set FSHβ -FSHR: The FSH or Follicle Stimulating Hormone is a glycoprotein hormone produced and secreted by adenohypophysis and contributes, in both sexes, the regulation of the development, and pubertal maturation of reproductive process. Polymorphism -211 G> T (rs 10,835,638) influences the FSH levels in serum. This polymorphism, which causes the substitution of a G with a T, is placed in the promoter of the gene -211bp upstream of the transcript start site of mRNA. A statistically significant association between serum levels of FSH and FSH genotypes was found: heterozygotes (GT) or homozygous (TT) have serum FSH significantly lower than WT subjects (GG). Many studies, including Tüttelmann in 2012, found a significant correlation between the subjects carriers of T with serum levels of FSH (lower 24% in TT than GG), the relationship with FSH / LH, with the testicular volume and concentration and sperm counts (lower by 36% and 34% in TT than GG). FSH is able to carry out its stimulatory effects on gametogenesis only if it binds to a specific receptor (FSHR). This receptor is located on the surface of the Sertoli cells in the testis and on the surface of the ovary granulosa. The variant 2039 A> G (rs 6166) characterizes the haplotype of exon 10. In the protein, the replacement 2039 A> G causes the substitution asparagine with serine. In women FSHR genotype related to these SNPs is the factor that most influences the ovarian responsiveness to FSH-treatment necessary for ovulation induction in the assisted fertilization techniques. The variant 2039 A> G reflects a reduced ovarian sensitivity in women requesting a dose of exogenous FSH higher in assisted fertilization techniques. It has been also shown a significant decrease of testicular volume by relating the various SNP 2039 A> G genotypes and -211GT - 211TT of FSHβ.
The studies by Selice (2011) and Ferlin (2011) have shown that the analysis of genes and FSHR FSHβ are valid pharmacogenetic approaches in males as treatment with FSH is able to induce an improvement in semen parameters only in a subgroup of oligospermic patients with a specific genotype related to these two genes.

More Less

About us

Company portrait

Dia-chem S.r.l. is born in 1989 from a group of managers who have gained significant experience for years in the world of national and international diagnostics. They collaborate with a team of researchers to develop and standardize kit in molecular biology. Dia-chem, since its creation, is focused on innovation and collaboration with the international scientific community. This international presence reinforces the capability to offer solutions to the clinical diagnostics and to anticipate clients needs.
Dia-chem S.r.l. is on the market with the following diagnostic lines: drug resistance, oncohematology, oncology and epigenetic, haemostasis and thrombosis, hemochromatosis, virology, neurology, infertility, panel for the predisposition to inflammation, predisposition to alimentary intolerance and recurring miscarriage. Our proposal is focused on quality, practicality and implementation of international reference techniques, with particular attention to the management costs.
Our main goal is to identify and satisfy clients needs. This implies solving their problems and anticipating their demands keeping in close touch. Customer advisory is a key element in our strategy for kit developing and production in order to satisfy the market needs and exceed expectations. Our core business is the molecular analysis of DNA, RNA and proteins carried out in molecular diagnostics labs. The modern and innovative analysis based on nucleic acids revelation offers many advantages over traditional methods for diagnostics. These procedures allow to reveal genetic mutations, chromosomal rearrangements, chromosomal translocations, insertions, deletions, viral, bacterial, parasitic diseases much faster and with a higher sensitivity and specificity. As genetic and protein target, the cause of a disease can be found more precisely, allowing the most suitable therapy to be adopted.
The molecular diagnostic in modern medicine provides the necessary tools for the development of new strategies in the fight against many diseases. Hospitals and diagnostic laboratories using these techniques require high sensitivity, high specificity, easiness of use, fast analytical timing and limited costs.
Dia-Chem offers a wide range of technical tests based on Real-Time Polymerase Chain Reaction (PCR) technique (PCR RFLP), Sanger sequencing, PCR Cold (RFLP) Cold PCR Sanger sequencing which can be provided both directly to the health operators and through distributors. These kits are independent from instrumentation and can be used on different analytical platforms such as: Rotor-Gene™ (Qiagen), LineGeneKTM (Bioer Technologies), iQ5, CFXTM (BioRad), SmartCycler™ (Cepheid), Applied Biosystems 7300/7500, StepOne, MX3005PTM, MX3000 PTM (Agilent Technologies).
Dia-chem S.r.l. is one of the founder partners of the technological district "CAMPANIA BIOSCIENCE s c a r l". It is registered in the "National register of research of Ministry of Education, University and Research" (MIUR) N.60236RGP.
During the past years Dia-chem has been participating to different projects such as:
"PON 0003PE_00060_8" as a partner of Clinical Pathology Department AOUP Federico II (Naples), supervisor Prof. F. Bequinot, titled: "pre-clinical development and evaluation of phase 0 and phase 1 of molecules having pharmaceutical nutraceutical and cosmeceutical action for already approved molecules".
And in POR "Terra del Buono" as leading subject of POR of Campania region in partnership with CNR-IEOS titled "Technological transfer project of first industrialization for high potential and innovative companies for fighting oncological diseases".

All kits in the catalogue are IVD and CE marked, conformed to 98/79 guideline.